Abstract 231P
Background
Overall survival (OS) is the optimal marker of efficacy for evaluation of treatments in randomized clinical trials (RCTs) but can take a considerable amount of time to mature. Evaluation of changes in tumor size through objective response rate (ORR) and progression free survival (PFS) has served as an early surrogate of OS however they are imperfect. Time to deterioration (TTD) in quality of life (QoL) measures could act as an early alternative patient centered surrogate of OS.
Methods
We utilised published phase 3 RCTs in solid malignancies that reported OS, PFS, ORR, and time to deterioration (TTD) evaluations of overall QoL or physical function (PF) published between 1st of January 2010 and 30th of June 2022. Weighted regression analysis was utilised to assess the relationship between PFS, ORR ratio, TTD QoL and TTD PF with OS. The coefficient of determination (R2) was used to quantify surrogacy.
Results
After identifying 9109 publications, 138 studies with 86199 patients were included for analysis. 47 RCT involved immunotherapy (IO) whilst 91 investigated non-IO agents. PFS (R2= 0.19) and ORR (R2= 0.05) were poor surrogates of OS. TTD QoL and TTD PF was available in 137 and 75 RCTs respectively. In the respected subset of studies, TTD QoL (TTD QoL R2= 0.18 vs. PFS R2= 0.19) and TTD PF (TTD PF R2= 0.10 vs PFS R2= 0.09) performed similarly to PFS as surrogates of OS. However, for IO agents, TTD PF (R2= 0.38) had a higher surrogacy to OS compared to PFS (R2= 0.19). Furthermore, combining PFS and TTD PF enabled improved prediction of OS (R2= 0.57). Importantly, TTD PF and PFS were not correlated with each other (R2= 0). TTD PF was not a surrogate endpoint of OS for non-IO trials.
Conclusions
Our trial level analysis identified TTD in PF as a potential marker of early OS in trials that utilized IO agents. It could potentially be used in conjunction with PFS to improve surrogacy in specific tumor types. Our results are based on published results and should be validated using patient-level data.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
226P - LongiBloodImmunoM: A multi-step analysis pipeline for longitudinal blood-based immunomonitoring for immunotherapy clinical trial
Presenter: Jiangfeng Ye
Session: Poster session 01
227P - Biomarkers for novel NK checkpoint inhibitor anti LLT1 antibody, ZM008: Patient transcriptome analysis
Presenter: M. S. Madhusudhan
Session: Poster session 01
228P - Biomarker discovery via meta-analysis of immunotherapy clinical trials in cancer
Presenter: Benjamin Haibe-Kains
Session: Poster session 01
230P - Fibroblast growth factor receptor (FGFR) co-alteration (co-alt) landscape and its impact on erdafitinib (erda) response in the phase II open-label, single-arm RAGNAR trial
Presenter: Yohann Loriot
Session: Poster session 01
232P - Identification of ‘secondary’ germline cancer predisposition variants from somatic tumour testing: Should we evolve towards universal screening?
Presenter: Alejandro Gallego Martinez
Session: Poster session 01